Laudanum of opium tincture prevails today only because opium tincture was sold prior to the Federal Food, Drug & Cosmetic Act of 1938. Its "grandfathered" status protects opium tincture from being required to undergo strict FDA drug reviews and subsequent approval processes. However, the FDA closely monitors the labeling of opium tincture. Bottles of opium tincture are required by the FDA to bear a bright red "POISON" label given the potency of the drug and the potential for overdose (see discussion about confusion with Paregoric below). Despite opium tincture being an "unapproved drug" as discussed above, a search of FDA's website
Drug Houses of Australia Drug Houses of Australia Drug Houses of Australia (DHA) was originally established in 1936 as an amalgamation of seven Australian pharmaceutical companies, notably A. M. Bickford & Sons. In 1970, DHA was taken over by the British bank Slater Walker. Drug Houses of Australia is now a leading generic pharmaceutics and Chinese proprietary medicine (CPM) manufacturer based in Jurong, Singapore. It was sold to Strides Arcolab through a share purchase agreement with Haw Par Healthcare Limited, Singapore in September 2006 for approximately SGD$19.7 million. It is currently a part of Strides Arcolab which is listed on both the Indian stock